InvestorsHub Logo
Followers 13
Posts 1812
Boards Moderated 0
Alias Born 03/29/2016

Re: fred198484 post# 27688

Thursday, 06/08/2017 5:15:51 PM

Thursday, June 08, 2017 5:15:51 PM

Post# of 38634
Thanks Fred, interesting development on the FDA side of things. We have had discussions in the past that FDA will remove those drugs that post a risk to abuse and public health. And, now it begins with ENDO's version. This just means more market shares for the new and improved version like Rexista, or PTIE Remoxy.

Sucks to be Endo but I wonder if what they would do? ENDO now merged with PAR have good relations with IPCI in the past. Between PTIE and IPCI, PTIE have bad track records on FDA approval, but supposedly they have a clear path now after the FDA requiring additional trials. There aren't that many choices out there for Oxycodone with ADF technology. It be interesting to see either PTIE or IPCI gets a deal signed. Still, IPCI is ahead in the race compare to PTIE who is waiting on year end results on the additional trials before filing for the fourth time with the FDA.

I'd say IPCI have better chance here. Recently EGLT ARYMO ER was covered by large payer in the US. All this indicates a favorable trend in embracing ADF technology on opioid pain killers.

It's all on the Purdue trial now, the sooner this ends the sooner we see a partnership. IPCI wanted Rexista as plug and play product, and that isn't happening with the law suite going on.